Every material Form 8-K Lakewood-Amedex Biotherapeutics Inc. has filed with the SEC since April 28, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Lakewood-Amedex Biotherapeutics made a corporate investor presentation available on July 15, 2026, describing its Bisphosphocin compound platform and its lead program, Nu-3, a topical antimicrobial gel for infected diabetic foot ulcers. The filing contains no financial results, guidance, or new financing, and the deck states that Phase 2a clinical trial milestones run from 3Q26 through 4Q26/1Q27 for top-line results.
Investor deck dated July 15, 2026, furnished as Exhibit 99.1 under Regulation FD and not deemed filed under the Exchange Act.
Deck lists Phase 2a trial milestones: clinical trial commences and first patient first visit in 3Q26; clinical trial complete in 4Q26; top-line results expected 4Q26/1Q27.
Intellectual property: 71 issued and 30 pending patents, with key filings providing protection through 2038 and recent applications through 2044.
Lakewood-Amedex Biotherapeutics Inc. (NASDAQ: LABT) appointed Dr. Joseph Tucker to fill a vacancy on its Board effective April 24, 2026. Dr. Tucker is CEO and Director of Enveric Biosciences, and his compensation includes $6,000 per quarter in stock and 33,784 warrants exercisable at $10.00 per share, which may affect shareholders through dilution if exercised.
Board appointment effective April 24, 2026, with a term until the 2027 annual meeting
Compensation of $6,000 per quarter, payable in common stock, plus 33,784 warrants at a $10.00 exercise price with a ten-year term
Warrants vest in four tranches of 8,446 on October 24, 2026, April 24, 2027, October 24, 2027, and April 24, 2028
Dr. Tucker is CEO and Director of Enveric Biosciences (NASDAQ: ENVB) and joins the Finance, Audit, Risk, Compensation, and Governance committees
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Lakewood-Amedex Biotherapeutics Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →